迈威生物与君实生物签署阿达木单抗注射液合作协议补充条款

财中社
27 Mar

  3月27日,迈威生物(688062)发布公告,2025年3月26日,公司及其全资子公司与君实生物及其全资子公司签署了关于阿达木单抗注射液合作开发协议的补充协议。

  具体而言,公司负责君迈康®的推广,按销售发货净收入的60%享有国内销售权益,君实生物则负责生产,享有40%的权益。此外,双方按50%:50%的比例分担国内研发费用及分享国际销售权益。

  2024年前三季度,迈威生物实现收入1.41亿元,归母净利润-6.94亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10